The FDA approval of Amgen, Inc’s (NASDAQ: AMGN) biosimilar version of Johnson & Johnson's (NYSE: JNJ) psoriasis treatment, Stelara, for multiple inflammatory diseases sent
Barclays analyst Dan Levy upgraded the rating on Ford Motor Company (NYSE: F) and General Motors Company (NYSE: GM) from Equal-Weight to Overweight with a
Piper Sandler analyst Alexander Goldfarb revised ratings on several real estate REITs amid higher interest rates environment and increased supply pressures scenario.
Invitation Homes Inc (NYSE: INVH) shares are on course to exit October with losses of around 7%.
Rent growth and occupancy are normalizing and should remain above the pre-COVID-19 pandemic averages in 2024, according to Oppenheimer.